{"id":"W4361953961","doi":"10.1158/1078-0432.c.6530597.v1","title":"Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Eli Lilly and Company; University of Toronto Scarborough; National Institutes of Health; Astellas Pharma; Genomic Health; Kowa Company; Society for Immunotherapy of Cancer; Cancer Prevention and Research Institute of Texas; Genentech; Amgen; Nancy Owens Memorial Foundation; Array BioPharma; Conquer Cancer Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; EMD Serono; Novartis; Ludwig Center at Harvard; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Astellas Pharma Global Development; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Breast cancer; Triple-negative breast cancer; Immune system; Tumor-infiltrating lymphocytes; Medicine; Tumor microenvironment; Cancer; Neoadjuvant therapy; T cell; CD3; Internal medicine; Immunology; CD8","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008033384,0.0001094858,0.0002260157,0.0003304449,0.0001319957,0.0002767433,0.0001285006,0.0001789536,0.001453731],"category_scores_gemma":[0.0016091,0.00008513159,0.0002162587,0.0003820857,0.0001586784,0.0001745009,0.0002112372,0.0001516029,0.0002057216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003480483,"about_ca_system_score_gemma":0.0002045598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006867546,"about_ca_topic_score_gemma":0.00193361,"domain_scores_codex":[0.9996597,0.0001278681,0.00004580197,0.00005808162,0.00008595335,0.00002276519],"domain_scores_gemma":[0.9988575,0.0003697079,0.0004236798,0.000112738,0.000112845,0.0001235006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01218779,0.0002270119,0.932843,0.0002446881,0.0002225389,0.0002011632,0.0001068011,0.0003255093,0.01647414,0.00005009885,0.0009883987,0.03612897],"study_design_scores_gemma":[0.0001347024,0.001415172,0.9925707,0.00002231813,0.0001553449,0.0006638567,0.00006458964,0.0003316539,0.003004389,0.00002718401,0.001602923,0.000007062015],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.9966916,0.0008056284,0.0001334182,0.0000629162,0.00000717591,0.00002097724,0.001105561,0.000007944736,0.00116482],"genre_scores_gemma":[0.9984742,0.0001524784,0.00008435317,0.0000648795,0.000006003615,0.00001820015,0.0009990527,0.000002090397,0.0001988024],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.001453731,"threshold_uncertainty_score":0.004863203,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08224299910603904,"score_gpt":0.3606547968998529,"score_spread":0.2784117977938138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}